NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Disc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 15, 2026 ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atlassian Corporation and its officers or directors [1] Group 1: Stock Performance and Analyst Opinions - On January 16, 2026, Citi reduced its price target for Atlassian stock from $240 to $210, citing concerns over the quality of revenue growth and the impact of code assistant platforms [3] - Following the downgrade, Atlassian's stock price dropped by $9.90, or 7.71%, closing at $118.55 per share on the same day [3]

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for allegedly concealing a significant increase in loan delinquencies during a specific period, leading to investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Sallie Mae securities from July 25, 2025, to August 14, 2025 [1]. - Investors have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. - The complaint claims that Sallie Mae misrepresented the nature of rising early-stage delinquencies, attributing them to seasonal trends while downplaying the effectiveness of their loss mitigation programs [3]. Group 2: Financial Impact - A TD Cowen report revealed that July delinquencies increased by 49 basis points month-over-month, which was above seasonal expectations [4]. - Following the report, Sallie Mae's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. on behalf of investors who acquired Fermi securities during the specified Class Period, alleging misleading statements regarding tenant demand and project funding [1][3]. Group 1: Lawsuit Details - The lawsuit targets Fermi Inc. for allegedly misleading investors about the demand for its Project Matador AI campus and the status of its funding [3]. - It is claimed that the construction financing for Project Matador was reliant on a single tenant's funding commitment, which posed a significant risk of withdrawal [3]. Group 2: Company Background - Fermi Inc. is headquartered in Amarillo, Texas, and aims to establish a network of large, grid-independent data centers powered by various energy sources including nuclear, natural gas, solar, and battery energy [2]. Group 3: Investor Information - Investors who purchased Fermi securities during the Class Period have until March 6, 2026, to seek appointment as lead plaintiff representatives [2].

PHILADELPHIA, Jan. 27, 2026 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating potential breach of fiduciary duties claims concerning Agilon Health, Inc. (NYSE: AGL) on behalf of the company's long-term investors. Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. CONTACT: KASKELA LAW LLC D. Seamus Kaskela, Esq. ...

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”), have until March 9, 2026 to seek appointment as lead plaintiff of the Ardent Health class action lawsuit. Captioned Postiwala v. Ardent Health, Inc., No. 26-cv-00022 (M.D. Tenn.), the Ardent Health class action lawsuit charges Ardent Health as well as cer ...

Core Viewpoint - Klarna Group plc is facing a class action lawsuit related to its September 10, 2025 IPO, alleging violations of the Securities Act of 1933 due to misleading offering documents and understated risks associated with its loss reserves [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Nayak v. Klarna Group plc, allows purchasers of Klarna securities from the IPO to seek appointment as lead plaintiff by February 20, 2026 [1][2]. - Klarna's IPO involved the issuance of approximately 34 million shares at an offering price of $40.00 per share [2]. - The lawsuit claims that Klarna's offering documents were materially false and omitted critical information regarding the risk of increased loss reserves shortly after the IPO [3]. Group 2: Financial Performance and Stock Impact - Following the IPO, Klarna reported a net loss of $95 million on November 18, 2025, and increased provisions for loan losses to $235 million, exceeding analyst estimates of $215.8 million [4]. - Provisions for loan losses represented 0.72% of gross merchandise volume, up from 0.44% the previous year [4]. - By the time the class action lawsuit commenced, Klarna's stock price had fallen to $31.31 per share, significantly below the IPO price of $40 [4]. Group 3: Legal Representation and Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Klarna securities in connection with the IPO to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [5]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].

The F5 class action lawsuit alleges that throughout the Class Period, defendants created the false impression that they possessed reliable information pertaining to F5's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. The complaint alleges that in truth, F5's optimistic claims, touting its purported best-in-industry security and overall emphasis and confidence in F5's ability to meet and capitalize on the growing security needs for ...

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. for alleged violations of securities laws, specifically related to misleading statements about the company's asset valuations and potential impairment charges [1][5]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Beyond Meat securities between February 27, 2025, and November 11, 2025, and encourages them to contact the Schall Law Firm before March 24, 2026 [2]. - The class has not yet been certified, meaning that affected investors are not currently represented by an attorney unless they take action [4]. Group 2: Allegations Against Beyond Meat - The complaint alleges that Beyond Meat made false and misleading statements regarding its long-lived assets, which were reported at a higher book value than their fair value [5]. - It is suggested that the company may need to record a non-cash impairment charge due to the discrepancies in asset valuation, leading to materially misleading public statements throughout the class period [5].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed by Bleichmar Fonti & Auld LLP on behalf of investors in Ardent Health securities, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Middle District of Tennessee [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].